Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Morphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 7/20 | 0.90 |
| ▸ | OPRD1 | P41143 | 10/20 | 0.90 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.90 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.90 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.90 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.90 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morphine SCHEMBL8374708 | 1.00 | OPRD1 (0.90) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL15055206 | 1.00 | OPRD1 (0.90) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL2443249 | 0.99 | OPRD1 (0.89) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL27790641 | 0.96 | OPRD1 (0.90) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL27547724 | 0.95 | OPRD1 (0.96) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL24599520 | 0.95 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL13696339 | 0.95 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL8049464 | 0.95 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL7987114 | 0.95 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL13076870 | 0.95 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230414604-A1 | MORPHINE FORMULATIONS | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2023-12-28 | — | — | US | claimed |
| US-20200345720-A1 | MORPHINE FORMULATIONS | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2020-11-05 | — | — | US | claimed |
| US-20190167665-A1 | MORPHINE FORMULATIONS | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2019-06-06 | — | — | US | claimed |
| US-20160175297-A1 | Morphine Formulations | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2016-06-23 | — | — | US | claimed |
| EP-2968132-A1 | INJECTABLE MORPHINE FORMULATIONS | Becton Dickinson France S.A.S (FR) | 2016-01-20 | — | — | EP | claimed |
| US-9192608-B2 | Morphine formulations | BECTON DICKINSON FRANCE S.A.S. (FR) | 2015-11-24 | — | — | US | claimed |
| US-20150246036-A1 | Morphine Formulations | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2015-09-03 | — | — | US | claimed |
| WO-2014140095-A1 | INJECTABLE MORPHINE FORMULATIONS | BECTON DICKINSON FRANCE S.A.S. (FR) | 2014-09-18 | — | — | WO | claimed |
| CN-104042565-A | Morphine formulations, kits comprising the same, and uses thereof | BECTON DICKINSON FRANCE SAS | 2014-09-17 | — | — | CN | claimed |
| EP-0767663-B1 | COMPOSITION COMPRISING MORPHINE, POLYPYRROLIDONE AND A POLYALKYLENEOXIDE | ALZA CORP (US) | 2002-04-03 | — | — | EP | claimed |
| EP-0767663-A1 | COMPOSITION COMPRISING MORPHINE, POLYPYRROLIDONE AND A POLYALKYLENEOXIDE | ALZA CORPORATION (US) | 1997-04-16 | — | — | EP | claimed |
| US-5593695-A | Morphine therapy | ALZA CORPORATION (US) | 1997-01-14 | — | — | US | claimed |
| WO-1996000066-A1 | COMPOSITION COMPRISING MORPHINE, POLYPYRROLIDONE AND A POLYALKYLENEOXIDE | ALZA CORPORATION (US) | 1996-01-04 | — | — | WO | claimed |
| US-5460826-A | Morphine therapy | ALZA CORPORATION (US) | 1995-10-24 | — | — | US | claimed |
| US-20250281680-A1 | DRUG-ELUTING SURGICAL ARTICLES AND RELATED METHODS | BIOSAPIEN INC (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250228846-A1 | MORPHINE FORMULATIONS | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2025-07-17 | — | — | US | disclosed |
| US-20250177290-A1 | DRUG-ELUTING SURGICAL ARTICLES AND METHODS OF USE THEREOF | BioSapien Inc. | 2025-06-05 | — | — | US | disclosed |
| EP-0557064-A1 | Modified release formulation | Euroceltique S.A. (LU) | 1993-08-25 | — | — | EP | disclosed |
| EP-0557065-A1 | Spheroid formulation | Euroceltique S.A. (LU) | 1993-08-25 | — | — | EP | disclosed |
| US-5202128-A | Oral administering | F. H. FAULDING & CO. LIMITED (AU) | 1993-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345720-A1 | MORPHINE FORMULATIONS | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
| US-20190167665-A1 | MORPHINE FORMULATIONS | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
| US-20250228846-A1 | MORPHINE FORMULATIONS | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
| US-20230414604-A1 | MORPHINE FORMULATIONS | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
| US-20150246036-A1 | Morphine Formulations | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
| US-20160175297-A1 | Morphine Formulations | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.